Siberian Tick Typhus (North Asian Tick Typhus): A Comprehensive Disease Characterization

Disease: Siberian Tick Typhus (North Asian Tick Typhus) MONDO ID: MONDO:0001154 Category: Infectious Disease (tick-borne, spotted fever group rickettsiosis) Causative agent: Rickettsia sibirica (NCBITaxon:35793), obligate intracellular Gram-negative alphaproteobacterium

Summary

Siberian tick typhus (STT), also called North Asian tick typhus, is an acute, generally mild and self-limited spotted fever group (SFG) rickettsiosis caused by the obligate intracellular bacterium Rickettsia sibirica. It is transmitted to humans by the bite of ixodid (hard) ticks, principally of the genera Dermacentor (notably D. nuttalli) and Haemaphysalis, across a broad Eurasian endemic zone spanning Siberia, Mongolia, northern China, and Central Asia. The disease is a zoonosis maintained in nature by a tick–small-mammal cycle in which humans are incidental hosts infected during outdoor activity. This report synthesizes nine cited findings and 23 reviewed papers into a complete disease-knowledge-base entry covering etiology, clinical phenotype, pathophysiology, immunity, diagnostics, epidemiology, treatment, prevention, and comparative/zoonotic biology.

Clinically, STT presents with the classic SFG triad of an inoculation eschar (tache noire) at the tick-bite site, fever, and a maculopapular rash, frequently accompanied by regional lymphadenopathy. A distinct subspecies, R. sibirica subsp. mongolitimonae, causes lymphangitis-associated rickettsiosis (LAR), in which roughly one-third of patients develop a rope-like lymphangitis extending from the eschar to draining lymph nodes. The underlying pathophysiology is a disseminated small-vessel vasculitis: bacteria delivered by the tick bite use surface-exposed outer-membrane proteins (OmpA/OmpB of the Sca family, plus Adr1/Adr2) to adhere to and invade vascular endothelial cells, producing endothelial injury, procoagulant/platelet activation, and the characteristic rash and eschar. Protective host defense is cell-mediated, dominated by IFN-γ-producing NK cells (innate phase) and CD8+ cytotoxic T cells (adaptive phase).

The prognosis is excellent. Doxycycline is the first-line curative therapy and produces rapid recovery with very rare sequelae. Diagnosis rests on indirect immunofluorescence assay (IFA) serology and PCR/sequencing of the ompA and gltA genes, ideally from an eschar biopsy or swab. There is no licensed vaccine and no genetic component to susceptibility; prevention is entirely based on personal anti-tick measures (repellents, permethrin-treated clothing, tick checks). This is fundamentally an environmentally/exposure-driven infectious disease, and its "risk factors," "inheritance," and "genetic testing" dimensions are therefore largely not applicable in the classical Mendelian sense.

Key Findings

Finding 1 — Etiology and vector (F001)

Siberian tick typhus is a spotted-fever-group rickettsiosis caused by Rickettsia sibirica, an obligate intracellular bacterium transmitted by ixodid ticks of the genus Dermacentor. Molecular surveillance in Inner Mongolia, China (2019; 408 ticks screened) detected R. sibirica in Dermacentor nuttalli ticks, with gltA haplotypes (G8/G10) and ompA haplotypes (O16/O19) clustering phylogenetically with R. sibirica PMID: 35934699. The comprehensive geographic review by Parola et al. classifies R. sibirica among the tick-borne SFG Rickettsia zoonoses PMID: 24092850, which states: "Tick-borne rickettsioses are caused by obligate intracellular bacteria belonging to the spotted fever group of the genus Rickettsia." The Inner Mongolia study identifies the principal regional vector: "The tick species Dermacentor nuttalli is considered the main vector carrying SFGR in Inner Mongolia."

This establishes the disease as infectious, not genetic: the sole necessary cause is inoculation of R. sibirica via a tick bite. Ontology anchors: causative organism — Rickettsia sibirica (NCBITaxon:35793); vector — Dermacentor nuttalli.

Finding 2 — Clinical triad, LAR subspecies, and benign course (F002)

STT produces the classic SFG clinical triad — inoculation eschar (tache noire), fever, and maculopapular rash — often with regional lymphadenopathy following a tick bite. A clinically important variant is caused by R. sibirica subsp. mongolitimonae, which produces lymphangitis-associated rickettsiosis (LAR). The defining review states: "This bacterium induces the lymphangitis-associated rickettsiosis, a still unfamiliar rickettsiosis that is mainly characterized by fever with a rope-like lymphangitis and/or lymphadenopathy and skin eschar occurring after tick bites" and "Sequellae are very rare and treatment with doxycycline is recommended" PMID: 24034636. The frequency of the lymphangitis feature is quantified in a second source: "Approximately, one-third of the patients with this infection experience lymphangitis from the inoculation eschar to the draining lymph nodes, and, in that case, the infection is named 'lymphangitis-associated rickettsiosis' (LAR)" PMID: 33969876.

Suggested HPO phenotype terms: Fever (HP:0001945), Skin rash (HP:0000988) / Maculopapular exanthema, Lymphadenopathy (HP:0002716), Skin ulcer/eschar (HP:0200042), Headache (HP:0002315), Myalgia (HP:0003326).

Finding 3 — Pathophysiology: endothelial infection, vasculitis, and procoagulant activation (F003)

The core pathophysiology of STT, shared across SFG rickettsioses, is a diffuse vasculitis with endothelial injury. R. sibirica infects vascular endothelial cells, producing a disseminated small-vessel vasculitis. Supporting evidence from the closely related SFG agent R. conorii (Mediterranean spotted fever, MSF) states: "The physiopathology of Mediterranean spotted fever includes diffuse vasculitis with endothelial injury" PMID: 20797742. In vivo studies of MSF patients demonstrate the downstream procoagulant cascade: "Our results provide biochemical evidence for the occurrence of TXA2-dependent platelet activation and thrombin generation in vivo, together with endothelial dysfunction" PMID: 8584998 — reflecting thromboxane-A2-dependent platelet activation, thrombin generation, and elevated endothelin-1.

Suggested GO terms: response to bacterium (GO:0009617), inflammatory response (GO:0006954), blood coagulation (GO:0007596), platelet activation (GO:0030168). Suggested CL/UBERON terms: endothelial cell (CL:0000115), blood vessel endothelium (UBERON:0004638), skin (UBERON:0002097).

Finding 4 — Diagnosis by IFA serology and ompA/gltA PCR (F004)

Diagnosis relies on indirect immunofluorescence assay (IFA) serology (seroconversion or ≥4-fold titer rise), plus PCR targeting the ompA and gltA genes with DNA sequencing, ideally performed on an eschar biopsy or swab. The standard molecular protocol is described as "a standard PCR reaction using primers suitable for hybridisation within the conserved region of genes coding for outer membrane protein A (ompA) and citrate synthase (gltA) and DNA sequencing were performed" PMID: 23168048. Non-invasive eschar sampling is now validated: "New approaches, such as swabbing of eschars to obtain material to be tested by PCR, have emerged in recent years and have played a role in describing emerging tick-borne rickettsioses" PMID: 24092850. In MSF biopsy series, PCR positivity reached 72.6% of samples, and IFA identifies the majority of serologically confirmed cases.

Finding 5 — Protective immunity is cell-mediated (NK cells + CD8+ T cells + IFN-γ) (F005)

Protective immunity to endothelium-targeting SFG rickettsiae is cell-mediated, not primarily antibody-driven. In murine models, resistant animals show higher frequencies of IFN-γ+ CD8+ T cells and cytotoxic NK cells; NK-deficient Rag−/−γc−/− mice show impaired clearance, severe hepatic thrombosis, and low serum IFN-γ. Key evidence: "these findings reveal that NK cells mediate the innate phase of host protection against infection with rickettsiae, most likely via IFN-γ production" and "NK cells are involved in preventing rickettsial infection-induced endothelial cell damage" PMID: 22617213. For adaptive immunity: "resistance to rickettsial infections is attributed to the induction of antigen-specific T cells, particularly CD8(+) T cells" PMID: 25043277, with the anti-Rickettsia CD8+ response peaking around 7 days post-infection and IFN-γ and granzyme B serving as correlates of protection.

Suggested CL terms: CD8-positive, alpha-beta T cell (CL:0000625), natural killer cell (CL:0000623). Suggested GO terms: interferon-gamma production (GO:0032609), T cell mediated cytotoxicity (GO:0001913).

Finding 6 — Surface proteins mediate endothelial invasion and are protective antigens (F006)

Rickettsial surface-exposed outer-membrane proteins — OmpA and OmpB (Sca autotransporter family), plus Adr1, Adr2, OmpW, Porin_4, and TolC — mediate adhesion to and invasion of vascular endothelial cells and are immunoprotective antigens. Proteomic surface labeling of R. rickettsii identified these SEPs, and immunization studies showed functional relevance: "sera from mice immunized with rAdr1, rAdr2, or rOmpW reduced R. rickettsii adherence to and invasion of vascular endothelial cells" and "Surface-exposed proteins (SEPs) of R. rickettsii may play important roles in its pathogenesis or immunity" PMID: 24950252. These proteins provide the molecular link between the initiating tick inoculation and the endothelial tropism that drives disease, and they are the targets of the ompA PCR used diagnostically (Finding 4).

Suggested GO cellular-component terms: outer membrane (GO:0019867), cell surface (GO:0009986). Suggested GO process term: entry into host cell (GO:0030260).

Finding 7 — Prevention is entirely non-immunological (personal anti-tick measures) (F007)

There is no licensed vaccine and no recommended routine chemoprophylaxis for SFG rickettsiosis. Prevention is entirely based on personal protective measures against tick bites: DEET/picaridin repellents, permethrin-treated clothing, tick checks, and prompt tick removal. The CDC position: "Personal protection measures to prevent human tick encounters from resulting in bites are widely recommended as the first line of defense against health impacts associated with ticks" PMID: 35364518. Efficacy is quantified: repellent/permethrin formulations showed "estimated repellencies ranging from 93 to 97%" in bioassays PMID: 32073128. Field durability is a caveat — 33% of permethrin-treated forester pants had no measurable permethrin after one year of wear PMID: 34958094.

Suggested NCIT-style intervention terms: insect repellent use; protective clothing; vector control.

Finding 8 — Animal reservoirs/sentinels and male-biased human exposure (F008)

Domestic and wild mammals act as sentinels and amplifying hosts in the SFG rickettsial cycle, and human seropositivity is male-associated, consistent with outdoor exposure rather than any genetic predisposition. Seroprevalence surveys show high SFG rickettsial IgG in animals: 57–59% of dogs and 59% of cats in Tasmania ("59% of cats and 57% of dogs were positive for antibodies" PMID: 20148824); and 58.5% of dogs, 48.1% of black rats, and 38.3% of humans in a Peruvian rural community. In that community, "only male gender was statistically associated with having IgG antibodies against Rickettsia spp. (p-value=0.049, chi-square test)" PMID: 39799873. The male predominance reflects occupational/recreational outdoor activity and tick exposure, reinforcing the environmental etiology.

Finding 9 — Doxycycline is curative; excellent prognosis (F009)

Doxycycline is the first-line curative therapy for STT and related SFG rickettsioses, producing rapid recovery with very rare sequelae. "Sequellae are very rare and treatment with doxycycline is recommended" PMID: 24034636, and a recent case series confirms "All patients were treated with doxycycline and recovered without complications" PMID: 40608626. The excellent prognosis, combined with the absence of a vaccine and reliance on vector avoidance (Finding 7), completes the management picture. Suggested NCIT term: Doxycycline (NCIT:C542); CHEBI: doxycycline (CHEBI:50845).

Full Disease-Knowledge-Base Entry (15 Sections)

1. Disease Information

STT is an acute febrile zoonotic infection of the SFG rickettsioses. Identifiers: MONDO:0001154; MeSH "Rickettsiosis, Siberian Tick" / "spotted fever"; ICD-10 A77.2 (Spotted fever due to Rickettsia sibirica); ICD-11 1C30.2. It is not an OMIM/Orphanet Mendelian entry (infectious, not genetic). Synonyms: North Asian tick typhus, North Asian tick-borne rickettsiosis, Siberian tick-borne typhus, Rickettsia sibirica infection. Information is derived from aggregated disease-level resources (case series, seroprevalence surveys, molecular surveillance) rather than individual EHR data.

2. Etiology

Causal factor: infectious — inoculation of R. sibirica through the bite of an infected ixodid tick (Finding 1). There are no genetic risk factors; susceptibility loci, causal variants, and modifier genes are not applicable to this infectious disease. Environmental/behavioral risk factors: outdoor occupational or recreational activity in endemic Eurasian foci (Siberia, Mongolia, northern China, Central Asia), spring–summer tick season, contact with tick-infested vegetation or animals; male sex is statistically associated with seropositivity as a proxy for exposure (Finding 8). Protective factors are behavioral (tick avoidance, repellents, protective clothing — Finding 7), not genetic. Gene–environment interactions: not applicable.

3. Phenotypes

Characteristics: adult-onset (exposure-driven, any age); acute onset; severity generally mild–moderate and self-limited; monophasic course resolving with treatment. Quality-of-life impact is transient and low given rapid response to doxycycline and rare sequelae.

4. Genetic/Molecular Information

Not applicable in the human-host sense — there are no causal human genes, pathogenic variants, modifier genes, epigenetic lesions, or chromosomal abnormalities. The relevant molecular genetics are pathogen-side: the R. sibirica genes ompA (outer membrane protein A) and gltA (citrate synthase) are used for molecular typing and phylogeny (Findings 1, 4), and surface-protein genes ompB, adr1, adr2, ompW encode virulence/adhesion factors (Finding 6).

5. Environmental Information

Infectious agent: Rickettsia sibirica (including subsp. sibirica and subsp. mongolitimonae). Vectors/environment: ixodid ticks — Dermacentor nuttalli (principal), other Dermacentor spp., Haemaphysalis, and (for mongolitimonae) Hyalomma and Rhipicephalus ticks in the broader region. Transmission occurs in natural steppe/forest-steppe habitats. No toxin, radiation, or pollution etiology.

6. Mechanism / Pathophysiology

Ordered causal chain:

1. An infected ixodid tick bites the human host and inoculates R. sibirica into the dermis (initiating exposure). → leads to
2. Bacteria use surface-exposed outer-membrane proteins (OmpA/OmpB, Adr1/Adr2) to adhere to and invade vascular endothelial cells at and beyond the bite site (Finding 6). → results in
3. Intracellular replication and cell-to-cell spread causing local endothelial injury and the inoculation eschar (tache noire); lymphatic spread produces regional lymphadenopathy and, for mongolitimonae, lymphangitis (LAR) (Finding 2). → leads to
4. Hematogenous dissemination and disseminated small-vessel vasculitis with endothelial injury (Finding 3). → results in
5. Procoagulant activation — thromboxane-A2-dependent platelet activation, thrombin generation, endothelial dysfunction (↑endothelin-1) — and increased vascular permeability (Finding 3). → produces
6. The clinical manifestations: maculopapular rash, fever, and (rarely) more severe vascular complications. Branch: in parallel, the host mounts a protective response —
7. NK cells (innate) and CD8+ T cells (adaptive), via IFN-γ and granzyme B, clear infected endothelium and prevent endothelial damage/thrombosis (Finding 5), leading to resolution — accelerated by doxycycline (Finding 9).

Steps 2, 3, 5, and 7 are supported by direct experimental evidence (largely from closely related SFG agents R. rickettsii and R. conorii, extrapolated to R. sibirica, which is noted as an inference where species-specific data are lacking). Molecular pathways: bacterial cell entry, host inflammatory response, coagulation cascade. Cell types: endothelial cells (target); NK cells, CD8+ T cells (protection). GO/CL/UBERON terms as listed under Findings 3, 5, 6.

7. Anatomical Structures Affected

• Primary organ/tissue: vascular endothelium (systemic small vessels) — UBERON:0004638 (blood vessel endothelium); skin (UBERON:0002097) at eschar and rash.
• Secondary: lymphatic vessels/nodes (lymphangitis, lymphadenopathy — UBERON:0000029 lymph node); potential liver/vascular complications in severe disease.
• Body systems: cardiovascular (vascular), integumentary, lymphatic/immune.
• Cell level: endothelial cell (CL:0000115). Subcellular: cytoplasm (intracellular replication) — GO cytoplasm (GO:0005737).
• Lateralization: eschar typically unilateral/localized (single bite site); rash generalized/bilateral.

8. Temporal Development

Onset: acute, after a short incubation following the tick bite; any age (exposure-dependent, adult-predominant). Course: monophasic, self-limited, resolving over days to weeks; prompt doxycycline shortens course. Progression: generally mild and non-progressive; sequelae very rare (Findings 2, 9). Remission: treatment-induced (rapid) or spontaneous in mild cases. Critical period: early doxycycline initiation optimizes outcome.

9. Inheritance and Population

Epidemiology: endemic across Siberia, Mongolia, northern China, Kazakhstan, and Central Asia; seasonal (tick-activity months). Animal seroprevalence is high (dogs 57–58.5%, cats 59%, rats 48%), indicating widespread enzootic circulation (Finding 8). Inheritance: not applicable (infectious). Penetrance/expressivity/anticipation/founder effects/consanguinity/carrier frequency: all not applicable. Demographics: male predominance in seropositivity (p=0.049), attributable to outdoor exposure (Finding 8); no ethnic genetic predisposition. Geographic distribution tracks the range of Dermacentor/Haemaphysalis vectors and their small-mammal reservoirs.

10. Diagnostics

Serology: IFA (reference standard) — seroconversion or ≥4-fold titer rise (Finding 4). Molecular: PCR of ompA and gltA with sequencing, from eschar biopsy or swab (non-invasive), or from blood/rash biopsy (Finding 4). Supportive labs: thrombocytopenia may be present. Clinical criteria: compatible triad (eschar + fever + rash) plus endemic tick exposure. Differential diagnosis: other SFG rickettsioses (MSF/R. conorii, R. slovaca TIBOLA/SENLAT, R. raoultii, R. aeschlimannii), tularemia, Lyme borreliosis, typhus group, and other eschar-forming tick-borne illnesses. Genetic/omics/newborn screening: not applicable.

11. Outcome/Prognosis

Excellent. With doxycycline, recovery is rapid and complete; "All patients... recovered without complications" PMID: 40608626. Mortality is very low for R. sibirica (in contrast to more virulent SFG agents such as R. rickettsii). Sequelae are very rare PMID: 24034636. Complications (severe vasculitis, thrombosis) are uncommon and associated with delayed treatment. Prognostic factors: timeliness of doxycycline, host immune competence (NK/CD8+ IFN-γ response — Finding 5), and comorbidity.

12. Treatment

First-line: Doxycycline (tetracycline-class; inhibits bacterial protein synthesis) — curative, rapid response (Finding 9). Alternatives for SFG rickettsioses include other tetracyclines and, in specific circumstances, chloramphenicol or fluoroquinolones/macrolides (agent- and patient-dependent). No advanced therapeutics (gene, cell, RNA, targeted, or immunotherapy) are relevant. Supportive care for fever/pain as needed. Pharmacogenomics: not applicable. NCIT/CHEBI: Doxycycline (NCIT:C542; CHEBI:50845).

13. Prevention

Entirely non-immunological (Finding 7). Primary prevention: personal anti-tick measures — DEET/picaridin repellents, permethrin-treated clothing (93–97% repellency), tick checks, prompt tick removal; environmental/vector control in high-risk settings. Secondary/tertiary: early recognition and doxycycline. Immunization: no licensed vaccine. Prophylaxis: routine post-bite antibiotics not recommended. Public health: health education for outdoor workers/travelers in endemic zones; note permethrin durability declines over ~1 year of wear (Finding 7 caveat).

14. Other Species / Natural Disease

Taxonomy of hosts/reservoirs: small mammals (rodents), dogs (Canis lupus familiaris, NCBITaxon:9615), cats (Felis catus, NCBITaxon:9685), and rats serve as reservoirs/sentinels with high seroprevalence (Finding 8). Vector: Dermacentor nuttalli and related ixodids. Zoonotic potential: STT is a zoonosis maintained in a tick–mammal cycle; humans are incidental hosts. Domestic animals are largely asymptomatic amplifying/sentinel hosts. Comparative pathology: the endothelial-tropism mechanism is conserved across SFG Rickettsia species and their mammalian hosts.

15. Model Organisms

Mouse models are the principal experimental system for SFG rickettsial immunity and pathogenesis: resistant/susceptible mouse strains, Rag−/−γc−/− NK-deficient mice, and challenge/immunization studies define the NK/CD8+/IFN-γ correlates of protection (Findings 5, 6). In vitro: vascular endothelial cell infection assays model adhesion/invasion (Finding 6). Most mechanistic data derive from R. rickettsii/R. conorii models and are extrapolated to R. sibirica; species-specific R. sibirica models are a knowledge gap. Cattle Cowdria (Ehrlichia) ruminantium work PMID: 9573061 provides comparative evidence that infected endothelial cells present antigen to protective T cells.

Mechanistic Model / Interpretation

 TICK BITE (Dermacentor nuttalli inoculates R. sibirica)
              │
              ▼
 [Surface proteins OmpA/OmpB, Adr1/Adr2]  ── adhere & invade ──►  VASCULAR ENDOTHELIAL CELLS
              │                                                          │
              ▼                                                          ▼
   Local injury → ESCHAR (tache noire)                     Hematogenous dissemination
   Lymphatic spread → lymphadenopathy / LAR (mongolitimonae)            │
                                                                        ▼
                                            DISSEMINATED SMALL-VESSEL VASCULITIS
                                                                        │
                                    ┌───────────────────────────────────┤
                                    ▼                                   ▼
                    Procoagulant activation                     Increased vascular
                    (TXA2 → platelets, thrombin,                permeability
                     ↑endothelin-1)                                     │
                                    └───────────────┬───────────────────┘
                                                    ▼
                                    FEVER + MACULOPAPULAR RASH
                                                    │
        ┌───────────────────────────────────────────┘
        ▼ (host defense branch)
 NK cells (innate) + CD8+ T cells (adaptive) ── IFN-γ, granzyme B ──► clear infected endothelium
        │
        ▼
 RESOLUTION  ◄──── accelerated by DOXYCYCLINE ────►  EXCELLENT PROGNOSIS, rare sequelae

The disease is best understood as a linear infectious cascade with a protective immune branch. The single initiating lesion (tick inoculation) is amplified through endothelial tropism into a systemic vasculitis; the same surface proteins that drive invasion are the antigens recognized by protective cellular immunity and the genetic targets of molecular diagnostics. Because there is no host genetic component, the disease's "risk," "protection," and "prevention" all operate at the level of exposure — explaining the male, outdoor-associated epidemiology and the vector-avoidance basis of prevention.

Evidence Base

Key strength: the mechanistic and immunological findings are internally consistent and cross-supported by multiple SFG species. Key caveat: much of the mechanistic/immunological detail derives from R. rickettsii and R. conorii rather than R. sibirica directly, and is applied by inference within the SFG.

Limitations and Knowledge Gaps

1. Species-specific data scarcity. Most pathophysiology (Findings 3, 5, 6) comes from R. conorii and R. rickettsii. R. sibirica-specific endothelial-invasion, immune-correlate, and virulence studies are limited; extrapolation within the SFG is reasonable but not proven for STT.
2. Epidemiology from proxies. The male-predominance and seroprevalence findings (F008) derive from non-endemic comparators (Peru, Tasmania) rather than core Eurasian STT foci; precise STT incidence/prevalence per 100,000 in Siberia/Mongolia/China was not quantified here.
3. No quantitative severity/QoL data. Phenotype frequencies are qualitative or drawn from related agents; formal QoL instruments have not been applied to STT.
4. Diagnostic performance figures (e.g., 72.6% PCR positivity) come from MSF series, not STT-specific cohorts.
5. No host-genetics dimension exists for this infectious disease, so Sections 4 and much of 9 are "not applicable" by nature rather than by data gap.
6. Vaccine/therapeutic pipeline for SFG rickettsioses remains preclinical; the protective-antigen work (F006) is promising but not yet translated.

Proposed Follow-up Actions

1. Quantify STT-specific epidemiology by mining Russian/Chinese/Mongolian surveillance and registry literature for incidence, seasonality, and age/sex distribution in core endemic foci.
2. Confirm R. sibirica-specific mechanisms: seek in vitro endothelial-invasion and murine immunity studies using R. sibirica itself to validate the extrapolated OmpA/OmpB/Adr and NK/CD8+/IFN-γ findings.
3. Compile a differential-diagnosis matrix distinguishing STT from co-circulating eschar-forming rickettsioses (R. slovaca, R. raoultii, R. aeschlimannii, R. conorii) by vector, geography, eschar location, and lymphadenopathy pattern.
4. Assess subspecies delineation: further characterize R. sibirica subsp. mongolitimonae (LAR) vs. subsp. sibirica clinical and molecular distinctions.
5. Evaluate protective-antigen vaccine candidates (Adr1/Adr2/OmpW) for cross-protection across SFG species, given the shared endothelial mechanism.
6. Ontology curation: finalize HPO/GO/CL/UBERON/NCIT/CHEBI mappings proposed above for knowledge-base ingestion.

Report compiled from 5 investigation iterations, 9 confirmed cited findings, and 23 reviewed papers. Evidence types span human clinical series, mouse and cattle models, in vitro assays, molecular surveillance, and seroprevalence surveys. Where R. sibirica-specific data were unavailable, findings from closely related spotted fever group Rickettsia are applied by explicit inference.